Synnovation's deal structure allows it to sell a single oncology asset for a large return to VCs, while the core drug discovery team remains to advance the rest of the pipeline. This 'hive-off' model offers a compelling alternative to traditional M&A or IPO exits.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

According to Kainova's CEO, the primary goal of a new biotech platform's first pharma partnership is not financial. It's to secure a prestigious partner name to validate the technology. This external validation, or "PR value," is more critical early on than maximizing the upfront payment, as it builds credibility for future, more lucrative deals.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?

In an industry where technology often fails, Vivtex prioritizes successful execution over deal volume. The CEO stresses that being honest about capabilities and delivering on promises is more crucial for long-term reputation and future partnerships than simply getting an initial deal signed.

To achieve a high-value acquisition, biotechs must first build a credible strategy to succeed independently, creating a position of strength. Concurrently, leaders should keep multiple potential suitors proactively informed on all business aspects—not just clinical data—to facilitate a competitive bidding process when the time comes.

Following a cautious 2025, dealmakers now demand tangible evidence of an asset's value. This "proof over promise" approach involves conducting integration planning during due diligence and heavily favoring targets with clearer regulatory pathways to minimize post-acquisition surprises.